Details of the Drug

General Information of Drug (ID: DM7GCVW)

Drug Name
Acalabrutinib
Synonyms
Calquence; UNII-I42748ELQW; I42748ELQW; Acalabrutinib [INN]; Acalabrutinib [USAN:INN]; Calquence (TN); Acalabrutinib(ACP196); Acalabrutinib (ACP-196); GTPL8912; Acalabrutinib (JAN/USAN/INN); SCHEMBL14637368; EX-A881; WDENQIQQYWYTPO-IBGZPJMESA-N; KS-000006AT; KS-000006AD; s8116; BDBM50175583; AKOS030526094; ZINC208774715; DB11703; CS-5356; DS-3326
Indication
Disease Entry ICD 11 Status REF
leukaemia 2A60-2B33 Approved [1]
Mantle cell lymphoma 2A85.5 Approved [2]
Chronic lymphocytic leukaemia 2A82.0 Phase 3 [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Affected Organisms
Humans and other mammals
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 465.5
Logarithm of the Partition Coefficient (xlogp) 3
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
Chemical Identifiers
Formula
C26H23N7O2
IUPAC Name
4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
Canonical SMILES
CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5
InChI
InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
InChIKey
WDENQIQQYWYTPO-IBGZPJMESA-N
Cross-matching ID
PubChem CID
71226662
ChEBI ID
CHEMBL3707348
CAS Number
1420477-60-6
UNII
I42748ELQW
DrugBank ID
DB11703
TTD ID
D09PQZ
INTEDE ID
DR0031
ACDINA ID
D00005
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine-protein kinase BTK (ATK) TTGM6VW BTK_HUMAN Inhibitor [2]
HUMAN bruton tyrosine kinase (BTK) TTOWPER BTK_HUMAN Inhibitor [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease leukaemia
ICD Disease Classification 2A60-2B33
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tyrosine-protein kinase BTK (ATK) DTT BTK 3.54E-01 0.24 0.56
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 1.34E-01 -2.79E-01 -7.05E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.81E-01 2.72E-01 6.95E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Acalabrutinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Acalabrutinib caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [8]
Arn-509 DMT81LZ Major Increased metabolism of Acalabrutinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [8]
Troleandomycin DMUZNIG Major Decreased metabolism of Acalabrutinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [8]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Acalabrutinib caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [8]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Acalabrutinib caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [8]
MK-8228 DMOB58Q Major Decreased metabolism of Acalabrutinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [8]
Tazemetostat DMWP1BH Moderate Increased metabolism of Acalabrutinib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [8]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Acalabrutinib and Avapritinib. Gastrointestinal stromal tumour [2B5B] [8]
Brigatinib DM7W94S Moderate Increased metabolism of Acalabrutinib caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [8]
PF-06463922 DMKM7EW Moderate Increased metabolism of Acalabrutinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [8]
Selpercatinib DMZR15V Moderate Decreased metabolism of Acalabrutinib caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [8]
IPI-145 DMWA24P Major Decreased metabolism of Acalabrutinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [8]
Arry-162 DM1P6FR Major Increased risk of bleeding by the combination of Acalabrutinib and Arry-162. Melanoma [2C30] [8]
LGX818 DMNQXV8 Major Increased risk of bleeding by the combination of Acalabrutinib and LGX818. Melanoma [2C30] [8]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Acalabrutinib and Siponimod. Multiple sclerosis [8A40] [9]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Acalabrutinib and Ocrelizumab. Multiple sclerosis [8A40] [10]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Acalabrutinib and Ozanimod. Multiple sclerosis [8A40] [11]
Fedratinib DM4ZBK6 Major Decreased metabolism of Acalabrutinib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [8]
Entrectinib DMMPTLH Moderate Decreased metabolism of Acalabrutinib caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [8]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Acalabrutinib caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [8]
Abametapir DM2RX0I Moderate Decreased metabolism of Acalabrutinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [12]
Lefamulin DME6G97 Moderate Decreased metabolism of Acalabrutinib caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [13]
Voxelotor DMCS6M5 Major Decreased metabolism of Acalabrutinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [8]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Acalabrutinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [8]
Larotrectinib DM26CQR Moderate Decreased metabolism of Acalabrutinib caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
LEE011 DMMX75K Major Decreased metabolism of Acalabrutinib caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
Elagolix DMB2C0E Moderate Increased metabolism of Acalabrutinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [8]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Acalabrutinib and Betrixaban. Venous thromboembolism [BD72] [8]
⏷ Show the Full List of 28 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Acalabrutinib 100 mg capsule 100 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 210259
2 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT04346199) Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.. U.S. National Institutes of Health.
5 AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19
6 FDA label of Acalabrutinib. The 2020 official website of the U.S. Food and Drug Administration.
7 Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020 Jun 5;5(48):eabd0110. doi: 10.1126/sciimmunol.abd0110. Epub 2020 Jun 5.
8 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
9 Cerner Multum, Inc. "Australian Product Information.".
10 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
11 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
13 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.